Melanotan I

Melanotan I (afamelanotide) is an injectable peptide that drives your skin to produce melanin without sun exposure. It is the same family of compound as

Melanotan II, but the cleaner version. Afamelanotide is selective for the pigment receptor (MC1R), so it tans you without the spontaneous erections, intense nausea, libido surge, and appetite crash that come with MT-II. It is also the only melanocortin tanning peptide that has been through proper phase 3 trials and gotten regulatory approval, marketed as Scenesse for a rare light-sensitivity disease called erythropoietic protoporphyria.

For cosmetic tanning, afamelanotide is off-label everywhere. The legitimate prescription product is a 16 mg slow-release implant placed by a doctor every 60 days at high cost, gated to EPP and vitiligo. What people actually use for tanning is grey-market lyophilised peptide, the same supply chain as MT-II, dosed as small daily subcutaneous injections. The pigment outcome is real and the side effect profile is genuinely milder than MT-II, but the same melanocyte stimulation that gives you a tan also darkens moles and freckles.

Deep-dive

Afamelanotide is a synthetic linear analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), the natural hormone your body releases to signal melanocytes to make pigment. The synthetic version swaps two amino acids ([Nle4, D-Phe7]-alpha-MSH), which makes it dramatically more potent than the natural peptide and resistant to enzymatic breakdown, so a small dose has a meaningful and long-lasting effect. It was the original molecule out of the University of Arizona tanning program in the 1980s, the one that gave the class its name. MT-II was synthesised later as a smaller cyclic version, more potent and less selective. Afamelanotide is the one that went through the regulatory process, MT-II is the one that escaped into the grey market.

Receptor selectivity is the central point. Afamelanotide is largely selective for the melanocortin-1 receptor (MC1R), the pigment receptor on melanocytes. MT-II hits MC1R, MC3R, MC4R, and MC5R indiscriminately, which is why MT-II also causes the erections (MC4R), the appetite suppression (MC3R/MC4R), and the flushing and nausea that hit hard in the first few doses. Afamelanotide produces some of those off-target effects too, headache and mild nausea are the most common reactions in trials, but at a fraction of the intensity. If you want the tan without the rest of the melanocortin pharmacology, this is the more targeted tool.

The mechanism in skin. Afamelanotide binds MC1R on melanocytes and switches on the cAMP-driven pathway that increases tyrosinase activity, the rate-limiting enzyme in melanin synthesis. The system preferentially shifts toward eumelanin, the darker brown-black pigment that absorbs UV well, rather than pheomelanin, the red-yellow pigment that is less protective and generates more oxidative damage when hit by UV. This is the same physiology you mobilise with sun exposure, the peptide just bypasses the UV-damage step. Beyond pigment, afamelanotide also has antioxidant and anti-inflammatory effects on skin cells and supports DNA repair pathways, which is the mechanistic basis for the EPP indication, those patients aren't just tanning, they are getting cellular-level photoprotection.

What the actual clinical evidence looks like. This is the most useful distinction between afamelanotide and MT-II. The Levine group at Arizona published the first proper randomised, placebo-controlled trial in JAMA in 1991, 28 healthy men receiving 10 subcutaneous injections over 12 days. The peptide produced significant, measurable skin darkening with no serious adverse events. A 1997 pharmacokinetic study confirmed that subcutaneous dosing is fully bioavailable, oral dosing gives nothing, and the plasma half-life is short, around 1-2 hours, with tanning that builds over days and lasts weeks beyond plasma clearance. Phase 2 and phase 3 trials in EPP, summarised in the 2015 NEJM trial by Langendonk et al., used the 16 mg implant every 60 days in 168 EPP patients across two multicentre trials and showed significantly more pain-free sun exposure and improved quality of life versus placebo. An 8-year observational study of 115 patients treated with the implant showed sustained benefit and no major safety signal, and a 2020 three-year observational study confirmed the same. The European post-authorisation safety study in 200 patients reported a consistent safety profile under real-world conditions. This is a real clinical evidence base, the kind MT-II will never have.

What that evidence does and doesn't tell you. All the long-term trial data is in EPP patients using the 16 mg implant every 60 days, not in healthy people using small daily subcutaneous injections for cosmetic tanning. The pharmacology generalises, but the dose, schedule, and population are different. Cosmetic dosing patterns come from community practice and the early Arizona trials, not from controlled trials of cosmetic use. So when something like the long-term mole behaviour is reported as clean in EPP patients, that is reassuring but not the same as data on a healthy person running daily injections for years.

Side effect profile in trials. Across the EPP trials, the most common adverse events were headache, nausea, fatigue, and implant-site reactions, all mild to moderate. No drug-related serious adverse events, no liver toxicity signal, no melanoma signal in the cohorts followed, including the over-70 subgroup. This is a much cleaner profile than what MT-II case reports describe (rhabdomyolysis, posterior reversible encephalopathy syndrome, priapism, renal infarction). The mechanism difference, MC1R selectivity, is the reason. If you tolerated MT-II badly because of the nausea, flushing, and sexual effects, those should be much milder on afamelanotide. If you tolerated MT-II fine, you may not notice a difference apart from cost and supply.

The mole question. Afamelanotide stimulates melanocytes everywhere, the same biology that gives MT-II its mole-darkening reputation. In the EPP trials and follow-ups, generalised skin pigmentation and darkening of existing moles and freckles is described, and the SCENESSE label explicitly recommends a full-body skin examination twice yearly to monitor pre-existing and new lesions. So expect moles to darken. What the trials have not shown is a melanoma signal, unlike MT-II where multiple case reports have flagged this. The honest read is that the long-term mole risk profile of afamelanotide looks better than MT-II, but afamelanotide still drives melanocyte activity and the monitoring discipline is the same. If you have a personal or family melanoma history, more than 50 moles, dysplastic nevus syndrome, or Fitzpatrick I skin with a lot of sun damage, this is not the right tool.

Women. MC1R biology is not sex-specific and the EPP trials enrolled women at roughly equal rates, with consistent efficacy and safety. There is no separate dose for women and the pigment response is similar. Unlike MT-II, afamelanotide does not have a strong libido or sexual-arousal effect because it doesn't hit MC4R significantly, so the unwanted libido side of MT-II is mostly absent. No safety data in pregnancy or breastfeeding, so it should be avoided in those periods regardless of mechanism.

Vitiligo. Worth knowing as a separate use case. Afamelanotide has been studied in combination with narrowband UVB phototherapy for vitiligo, with the most recent phase 3 work (CUV 105) actively running. Earlier phase 2 evidence showed faster and better repigmentation when the peptide is added to NB-UVB compared to NB-UVB alone, with the strongest effect in darker skin types. A practical wrinkle is that in fair-skinned vitiligo patients, the peptide also darkens the normal skin, which increases the contrast with the patches and can be cosmetically unwelcome.

Afamelanotide vs MT-II in practice. Same family, different trade-offs. Afamelanotide is cleaner, has actual trials, is the only one with a regulatory pathway, but the prescription implant is expensive and gated, and the grey-market injectable version costs more and is less commonly stocked than MT-II. MT-II is cheaper, more widely available, works faster (people often see colour within 1-2 weeks vs 2-3 weeks for afamelanotide), and comes with the full melanocortin side effect package. If sexual side effects are something you want or don't mind, MT-II is the everyday answer. If you specifically want pigment with the least extra pharmacology, afamelanotide is worth the price difference.

Dosage:

Afamelanotide comes in two formats. The legitimate Scenesse implant is 16 mg, placed subcutaneously by a clinician every 60 days, sustained-release. That is what the EPP and vitiligo trials used. For cosmetic use it is off-label, very expensive, and most prescribers will not place it for tanning

The grey-market form is lyophilised powder reconstituted with bacteriostatic water and injected subcutaneously, same supply chain and technique as MT-II. Community dosing protocols come from the Arizona-era trials, not from validated cosmetic protocols

Loading phase: 0.5-1 mg subcutaneous daily for 10-14 days. Many people start lower (0.25 mg) to gauge any nausea or headache before going up. Visible pigment builds over 2-3 weeks

Maintenance: 0.5-1 mg subcutaneous once or twice weekly to hold the colour. The tan fades over 6-8 weeks if you stop, which is roughly twice the persistence of MT-II

Timing: evening dosing is common because any mild flushing or nausea hits early and you sleep through it. Some sun or sunbed exposure on top accelerates visible results but is not required. Stacking heavy UV on top of a melanocyte stimulator compounds the underlying risk and undermines the point of using the peptide

Reconstitution and storage: keep reconstituted peptide refrigerated and use clean technique. With grey-market product, purity, sterility, and actual peptide content are unverifiable, that is itself a dosing problem

Women: same dose range and same logic, no separate scale. The libido and sexual-effect concern that applies to MT-II largely doesn't apply here, but the mole-darkening concern does

Don't stack with MT-II or with high-dose UV. Stacking another melanocortin agonist on top adds the MC3R/MC4R side effects you came to afamelanotide to avoid. Adding aggressive UV on top adds to the melanocyte stimulation burden

Here's what you can expect:

Pigment builds slower than with MT-II. Most people see noticeable colour at 2-3 weeks of daily dosing, and a full tan at 4-6 weeks. Fair-skinned people see the biggest visible change, dark-skinned people see a smaller relative shift. The colour holds with weekly maintenance dosing and fades over 6-8 weeks if you stop.

Acute side effects are usually much milder than with MT-II. A mild headache, occasional nausea, and some warmth or flushing in the first hour after a dose are the most common reports, all of which tend to settle within the first week. Most people don't get the strong yawning, stretching, or sexual effects that define the MT-II experience.

Moles and freckles will darken, this is the mechanism working as designed and is not avoidable. Take baseline photos, get a full-body skin check, and have a real plan for monitoring before you start.

Side effects & risks:

Headache, nausea, fatigue, and injection-site reactions are the consistent findings across the EPP trials, mild to moderate, usually settle in the first week or two. These are the dominant side effects rather than the libido and flushing complex that defines MT-II

Generalised skin darkening and darkening of existing moles and freckles. This is the mechanism working, expected and largely permanent for the duration of treatment. The Scenesse label explicitly flags this and recommends twice-yearly full-body skin examinations to monitor

Melanoma concern. Afamelanotide stimulates melanocytes, the cells involved in melanoma. The clinical trial and 8-year observational data have not shown a melanoma signal, which is a meaningful difference from the case reports that exist for MT-II. The mechanistic concern doesn't disappear, but the data we have so far is reassuring. A personal or family history of melanoma or dysplastic naevi is still a reason not to use this

GI and CNS effects like nausea, headache, fatigue are dose-dependent and respond to lower dosing or evening timing

Sexual side effects are uncommon, the opposite of MT-II. If they appear they tend to be mild and short-lived, this is the MC1R selectivity working

Cardiovascular. Melanocortin agonists can shift blood pressure and heart rate slightly. The EPP trials didn't flag this as a problem but a baseline reading is sensible if you have any cardiovascular history

Liver and kidney. The phase 3 trials and long-term observational data have not shown hepatic or renal toxicity. The serious case reports clustered around MT-II (rhabdomyolysis, renal infarction, posterior reversible encephalopathy syndrome) have not been seen with afamelanotide in trial settings

Pregnancy and breastfeeding: avoid. No human safety data

Supply quality. Grey-market product purity is unverifiable. This is a sterility, dosing accuracy, and contamination risk, not a property of the molecule itself. It is the dominant practical risk if you are not using the prescription implant

🩸

Blood markers

Full-body skin check by a dermatologist, baseline before starting. Not bloodwork but the single most important assessment. Get documented photos of your moles so future changes are judged against a real reference. Recheck every 6 months while using, the same cadence the Scenesse label recommends. Have anything actually changing in size or shape assessed properly rather than written off as drug effect.

Blood pressure and heart rate, baseline. Useful reference point given the receptor class, even though the trial data is reassuring.

Liver function (ALT, AST) and kidney function (creatinine, eGFR), baseline if you plan long-term use, especially with grey-market product where purity is unverifiable. The trial data on the prescription product is clean, but baseline numbers give you something to check against if you ever feel unwell on it.

Who actually needs what: everyone using afamelanotide should get the baseline derm check and 6-monthly skin surveillance, this is non-negotiable given the mechanism. Blood pressure and heart rate baseline is quick and worth having. Liver and kidney baseline matters most for long-term grey-market users and anyone with existing organ issues. Anyone with personal or family melanoma history, dysplastic naevi, or more than 50 moles should treat that as a reason not to use this at all rather than something to monitor around.

Approved as Scenesse (16 mg implant) for erythropoietic protoporphyria in the US, EU, and Australia. Cosmetic use is off-label everywhere and the injectable grey-market form is unregulated.